I39T (p.Ile39Thr) variant of C5 (Complement C5)

I39T (p.Ile39Thr) in C5 (Complement C5) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as uncertain significance in the context of Eculizumab, poor response to; Complement component 5 deficiency; not provided. The available variant effect predictions contribute to a CATVariant prioritization score of 0.37 / 1. The record also includes population frequency data and structural context.

I39T (p.Ile39Thr) variant details